MFSD2A: A Potential Drug Target and Biomarker (G84879)

Target Name: MFSD2A

NCBI ID: G84879

MFSD2A

MFSD2A: A Potential Drug Target and Biomarker

MFSD2A (Mucosal-Focal Systemic Dysregulation 2A) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. MFSD2A is a key regulator of gene expression in the immune system and has been shown to play a role in the regulation of immune cell function, differentiation, and inflammation.

The MFSD2A gene was identified in the human body as a potential drug target due to its involvement in the regulation of immune cell function. MFSD2A has been shown to regulate the production and function of natural killer cells, which are a critical part of the immune system that are responsible for detecting and destroying cancer cells. MFSD2A has also been shown to regulate the production and function of T cells, which are another important part of the immune system that play a key role in regulating the immune response.

In addition to its role in immune cell function, MFSD2A has also been shown to be involved in the regulation of inflammation. MFSD2A has been shown to regulate the production of pro-inflammatory cytokines, which can contribute to the development of inflammatory diseases. MFSD2A has also been shown to play a role in the regulation of inflammation-related pain signaling, which can contribute to the development of chronic pain.

As a potential drug target, MFSD2A has been shown to have a wide range of potential therapeutic applications. For example, MFSD2A has been shown to be a potential therapeutic target for cancer, including breast, ovarian, and colorectal cancers. MFSD2A has also been shown to be involved in the regulation of neurodegenerative disorders, including Alzheimer's and Parkinson's diseases. MFSD2A has also been shown to be involved in the regulation of autoimmune diseases, including rheumatoid arthritis and multiple sclerosis.

In addition to its potential therapeutic applications, MFSD2A has also been shown to have a wide range of potential biomarker applications. For example, MFSD2A has been shown to be a potential biomarker for cancer, including breast, ovarian, and colorectal cancers. MFSD2A has also been shown to be a potential biomarker for neurodegenerative disorders, including Alzheimer's and Parkinson's diseases. MFSD2A has also been shown to be a potential biomarker for autoimmune diseases, including rheumatoid arthritis and multiple sclerosis.

MFSD2A has also been shown to have a wide range of potential applications in basic research. For example, MFSD2A has been shown to be involved in the regulation of immune cell function and inflammation, which can be important targets for researchers studying the immune system and its role in disease. MFSD2A has also been shown to be involved in the regulation of cell signaling pathways, which can be important targets for researchers studying the regulation of cellular processes.

Overall, MFSD2A is a promising candidate for a drug target and biomarker for a wide range of diseases. Further research is needed to fully understand the role of MFSD2A in the immune system and its potential therapeutic and biomarker applications.

Protein Name: MFSD2 Lysolipid Transporter A, Lysophospholipid

Functions: Sodium-dependent lysophosphatidylcholine (LPC) symporter, which plays an essential role for blood-brain barrier formation and function (PubMed:24828040, PubMed:34135507, PubMed:32572202). Specifically expressed in endothelium of the blood-brain barrier of micro-vessels and transports LPC into the brain (By similarity). Transport of LPC is essential because it constitutes the major mechanism by which docosahexaenoic acid (DHA), an omega-3 fatty acid that is essential for normal brain growth and cognitive function, enters the brain (PubMed:34135507, PubMed:26005868). Transports LPC carrying long-chain fatty acids such LPC oleate and LPC palmitate with a minimum acyl chain length of 14 carbons (By similarity). Does not transport docosahexaenoic acid in unesterified fatty acid (By similarity). Specifically required for blood-brain barrier formation and function, probably by mediating lipid transport (By similarity). Not required for central nervous system vascular morphogenesis (By similarity). Acts as a transporter for tunicamycin, an inhibitor of asparagine-linked glycosylation (PubMed:21677192). In placenta, acts as a receptor for ERVFRD-1/syncytin-2 and is required for trophoblast fusion (PubMed:18988732, PubMed:23177091)

The "MFSD2A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MFSD2A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets